Live Feeds
● TRACKER Updated 2d ago · 82 sources tracked

Moderna Shares More Than Double on Success of mRNA Cancer Vaccine

Moderna shares have more than doubled after Phase 3 data showed its personalized mRNA cancer vaccine intismeran, combined with Merck's Keytruda, cut the risk of melanoma recurrence or death by 42%. The company reported a $162 million profit for Q3 on $1.3 billion in revenue, driven partly by a 29% increase in foreign COVID deals. Full-year revenue growth guidance was raised to 15-25%. Moderna also resolved patent disputes with GSK. The stock recovered to close at $241 after an October selloff.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (82)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Moderna shares more than doubled after Phase 3 data showed its personalized mRNA cancer vaccine intismeran, combined with Merck's Keytruda, cut the risk of melanoma recurrence or death by 42%.
  • ✓ The company reported a $162 million profit for Q3 on $1.3 billion in revenue, driven partly by a 29% increase in foreign COVID deals.
  • ✓ Moderna raised its full-year revenue growth guidance to 15-25% and resolved patent disputes with GSK.
  • ✓ The global biotechnology market is valued at USD 2.02 trillion in 2026 and is projected to reach USD 6.34 trillion by 2035 at a CAGR of 13.61%.
🛡️ Source Corroboration: 82 independent reporting domains (95% confidence) ⏱ Read time: ~2 min

What changed

Recent industry analysis confirms strong 2026 financial results across major biotechnology firms alongside ongoing medical research into broader applications for mRNA technology.

Live updates

  1. Moderna Stock Surges Following Positive mRNA Cancer Vaccine Data

    Moderna shares have more than doubled after Phase 3 data showed its personalized mRNA cancer vaccine intismeran, combined with Merck's Keytruda, cut the risk of melanoma recurrence or death by 42%. The company reported a $162 million profit for Q3 on $1.3 billion in revenue, driven partly by a 29% increase in foreign COVID deals. Full-year revenue growth guidance was raised to 15-25%. Moderna also resolved patent disputes with GSK. The stock recovered to close at $241 after an October selloff.

    Why it matters

    The global biotechnology market sits at USD 2.02 trillion in 2026 and is projected to reach USD 6.34 trillion by 2035 at a compound annual growth rate of 13.61%. Leading biotech companies raised their 2026 outlooks after third-quarter results, while large drugmakers raced to refill pipelines. Separately, research explores whether COVID-19 mRNA vaccines could help existing immunotherapies work better.

    What is confirmed

    • Moderna shares more than doubled after Phase 3 data showed its personalized mRNA cancer vaccine intismeran, combined with Merck's Keytruda, cut the risk of melanoma recurrence or death by 42%.
    • The company reported a $162 million profit for Q3 on $1.3 billion in revenue, driven partly by a 29% increase in foreign COVID deals.
    • Moderna raised its full-year revenue growth guidance to 15-25% and resolved patent disputes with GSK.
    • The global biotechnology market is valued at USD 2.02 trillion in 2026 and is projected to reach USD 6.34 trillion by 2035 at a CAGR of 13.61%.

    Still unconfirmed

    • mRNA vaccines could potentially help existing cancer immunotherapies work more effectively based on links between COVID-19 vaccination and cancer survival.

    What to watch next

    • Commercialization progress and regulatory submissions for intismeran.
    • Additional clinical data combining mRNA vaccines with cancer immunotherapies.
    Sources used for this update (4)
    1. theconversation.com — New cancer frontiers: Could COVID vaccines help make treatments more effective?
    2. finance.yahoo.com — Moderna: Can the Vaccine Business Fund Its Next Phase of Growth?
    3. decodingbio.substack.com — BioByte 180: Maps Against Cancer
    4. uk.finance.yahoo.com — Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dol....
    confidence 95%
  2. Moderna Shares Surge on Melanoma Vaccine Success With Keytruda

    Moderna shares have more than doubled after Phase 3 data showed its personalized mRNA cancer vaccine intismeran, combined with Merck's Keytruda, cut the risk of melanoma recurrence or death by 42%. The company reported a $162 million profit for Q3 on $1.3 billion in revenue, driven partly by a 29% increase in foreign COVID deals. Full-year revenue growth guidance was raised to 15-25%. Moderna also resolved patent disputes with GSK. The stock recovered to close at $241 after an October selloff.

    Why it matters

    The melanoma data represents the first Phase 3 success for an mRNA cancer vaccine, validating Moderna's platform beyond COVID-19. Investors are now pricing in a potential multi-billion dollar oncology franchise alongside the company's respiratory vaccine pipeline. The Q3 profit marks a sharp turnaround from pandemic-era losses and signals commercial maturity.

    What is confirmed

    • Moderna shares more than doubled following successful Phase 3 trial results for its personalized cancer vaccine.
    • The intismeran vaccine combined with Merck's Keytruda reduced the risk of melanoma recurrence or death by 42%.
    • Moderna reported a $162 million profit for the third quarter on $1.3 billion in revenue.
    • Full-year revenue growth guidance was raised to between 15% and 25%.
    • Foreign COVID deals increased 29% in the quarter.
    • The stock recovered to close at $241 after an October selloff.
    • Moderna resolved patent disputes with GSK.

    Still unconfirmed

    • One melanoma headline turned a $63 stock into a market darling, with shares up over 600% this year.

    What to watch next

    • FDA regulatory pathway and potential approval timeline for intismeran in melanoma
    • Additional Phase 3 readouts in other cancer types using the mRNA platform
    • Merck's commercial strategy and pricing for the Keytruda combination regimen
    Sources used for this update (2)
    1. www.mmm-online.com — Commercialization successes and cost cuts define Q3 pharma earnings
    2. finance.yahoo.com — Moderna Is Up Over 600% This Year. Here’s What Jim Cramer Learned in His Exclusive
    confidence 90%
  3. Moderna Shares Surge on Cancer Vaccine Success and Strong Q3

    Moderna shares have more than doubled following successful trial results for its personalized cancer vaccine. The company reported a $162 million profit for the third quarter, driven by $1.3 billion in revenue and a 29% increase in foreign COVID deals. Full-year revenue growth guidance was raised to between 15% and 25%. Phase 3 data demonstrated that the intismeran vaccine, when combined with Merck's Keytruda, reduced the risk of melanoma recurrence or death by 42%. The stock previously recovered to close at $241 after an October selloff, and the company also resolved patent disputes with GSK.

    Why it matters

    The surge in stock value reflects growing market enthusiasm for mRNA applications beyond infectious diseases. The successful combination of Moderna's personalized vaccine with Merck's Keytruda marks a significant milestone in oncology treatment. Meanwhile, the company strengthened its financial position through steady COVID-related international sales and the resolution of legal hurdles regarding GSK patents.

    What is confirmed

    • Moderna reported a $162 million profit for the third quarter.
    • Quarterly revenue reached $1.3 billion with a 29% increase driven by foreign COVID deals.
    • Moderna raised its full-year revenue growth guidance to between 15% and 25%.
    • Phase 3 data confirmed the intismeran vaccine combined with Merck's Keytruda cut melanoma recurrence or death risk by 42%.
    • The company stock previously recovered to close at $241 following an October selloff.
    • Moderna cleared patent disputes involving GSK.

    What to watch next

    • Further regulatory developments and commercial rollout plans for the intismeran cancer vaccine
    • Subsequent quarterly financial reports to evaluate sustained revenue growth from foreign COVID deals
    Sources used for this update (2)
    1. stocktwits.com — Stocktwits - Stock Market Live Quotes, Social Community...
    2. www.fortune.com — Jensen Huang’s net worth drops $10 billion as Nvidia stock slides in the fallout of affair scandals | Fortune
    confidence 100%
  4. Moderna Posts Profit and Raises 2026 Outlook on Vaccine Data

    Moderna reported a $162 million profit for the third quarter and raised its full-year revenue growth guidance to between 15% and 25%. Quarterly revenue reached $1.3 billion, bolstered by a 29% increase driven by foreign COVID deals alongside enthusiasm for its personalized cancer vaccine. The company stock previously recovered to close at $241 following an October selloff. Phase 3 data confirmed that the intismeran vaccine combined with Merck's Keytruda cut the risk of melanoma recurrence or death by 42%. Additionally, Moderna cleared patent disputes involving GSK.

    Why it matters

    The recent financial results show that Moderna is expanding beyond its core pandemic products as commercial interest builds around its oncology pipeline. The personalized cancer vaccine, developed alongside Merck, remains a primary driver of investor sentiment and stock performance this year. Meanwhile, improved international COVID product sales and resolved patent disputes with GSK have further strengthened the company balance sheet.

    What is confirmed

    • Moderna posted a $162 million profit for the third quarter of 2026.
    • Moderna raised its full-year 2026 revenue growth guidance to 15% to 25%.
    • Quarterly revenue reached $1.3 billion.
    • The intismeran vaccine combined with Keytruda reduced the risk of melanoma recurrence or death by 42%.

    Still unconfirmed

    • The CEO expects the personalized cancer vaccine to work in more cancers than melanoma.

    What to watch next

    • Further clinical data regarding the efficacy of the cancer vaccine across other cancer types beyond melanoma.
    • Quarterly performance reports to confirm if international COVID deals and new revenue guidance targets are met.
    Sources used for this update (8)
    1. fortune.com — Hachette’s CEO says AI shortcuts are creating a ‘worse C-suite'
    2. www.cnbc.com — Moderna (MRNA) earnings Q3 2026 - CNBC
    3. www.fool.com — Moderna Just Gave Investors Yet Another Thing to Cheer About
    4. www.techtimes.com — Moderna Posts $162M Profit, Raises Outlook as Cancer Vaccine ...
    5. finance.yahoo.com — Moderna Stock Rises 8% in Five Sessions as CEO Sees Cancer ...
    6. www.tikr.com — Moderna Stock Rises 8% in Five Sessions as CEO Sees Cancer ...
    7. blockonomi.com — Moderna (MRNA) Stock: Rally 7.38% as $1.3B Revenue and ...
    8. finance.yahoo.com — “More Cancers Than Melanoma”: Moderna Is Up 750% in 2026. Take Profits, or Buy More?
    confidence 95%
  5. Moderna Shares Volatile Following Cancer Vaccine Data Leak

    Moderna shares dropped as much as 25% on Thursday after trial data for its cancer vaccine leaked. This volatility follows a period of rapid growth where the stock hit a 52-week high of $258.72 on Wednesday. Despite the leak, the leaked data showed positive results and significant efficacy when the vaccine is paired with Merck's immunotherapy. Separately, Moderna reported four confirmed responses among 11 heavily pretreated multiple myeloma patients in early Phase 1/2 data for its investigational mRNA-2808 treatment.

    Why it matters

    Moderna is pivoting toward oncology through a partnership with Merck to develop personalized mRNA cancer vaccines. These treatments aim to reduce melanoma recurrence and target other tumor types. The company's market valuation has been driven by the perceived success of these mRNA applications.

    What is confirmed

    • Moderna shares reached a 52-week high of $258.72 on Wednesday.
    • Moderna shares fell as much as 25% Thursday following a leak of cancer vaccine trial data.

    Still unconfirmed

    • Moderna's investigational mRNA-2808 showed four confirmed responses among 11 heavily pretreated multiple myeloma patients in early Phase 1/2 data.
    • mRNA demand drove growth and led Maravai LifeSciences to raise full-year guidance.

    What to watch next

    • Presentation of mRNA-2808 results at the American Society of Hematology meeting in December
    Sources used for this update (4)
    1. rocketnews.com — Moderna shares plunge after cancer vaccine data leaks ...
    2. finance.yahoo.com — Maravai LifeSciences (MRVI) Q3 2026 Earnings Call Transcript
    3. finance.yahoo.com — Moderna's Cancer Vaccine Is Incredibly Promising, but This ...
    4. www.marketbeat.com — Moderna (NASDAQ:MRNA) Reaches New 1-Year High - Here's What ...
    confidence 90%
  6. Moderna Stock Surges on Cancer Vaccine Trial Success

    Moderna shares have surged roughly 650% to 652% in 2026, making the biotech firm the top performer in the S&P 500. The massive stock rally is driven by intense investor enthusiasm for intismeran autogene, a personalized mRNA cancer vaccine developed in partnership with Merck. When used alongside Keytruda, the custom treatment significantly reduces the risk of melanoma recurrence in clinical trials. Despite the explosive market gains and a strategic corporate pivot toward oncology, analysts caution that the valuation may be running ahead of itself while the technology awaits proof in other tumor types.

    Why it matters

    Moderna has experienced a major financial resurgence after struggling following the end of the COVID-19 pandemic. The soaring market valuation is tightly bound to its oncology portfolio, specifically late-stage clinical data targeting melanoma left behind after surgery. CEO Stéphane Bancel stated that trial outcomes could improve further with extended patient follow-up.

    What is confirmed

    • Moderna shares have surged roughly 650% to 652% in 2026, making it the top performer in the S&P 500.
    • The stock rally is driven by clinical trial results for a personalized mRNA cancer vaccine developed with Merck, known as intismeran autogene.
    • Moderna shares traded as high as $225.00 and closed at $222.76 during mid-day trading following a 4% increase.

    Still unconfirmed

    • Wall Street is potentially overpricing the cancer breakthrough before it has proven effective outside of a single tumor type.

    What to watch next

    • Whether the personalized mRNA cancer vaccine proves effective in tumor types other than melanoma
    • Upcoming regulatory milestones and commercial developments for intismeran autogene
    Sources used for this update (12)
    1. finance.yahoo.com — Yahoo Finance - Stock Market Live, Quotes, Business & Finance News
    2. 247wallst.com — Moderna Jumps 4% Despite William Blair Downgrade on Valuation ...
    3. www.zmescience.com — A Roman Coffin at Westminster Abbey Held the Wrong Body for More Than 1,000 Years
    4. www.uchealth.org — Personalized mRNA melanoma vaccine with Keytruda shows ...
    5. www.research.va.gov — VA Research News Briefs
    6. uk.finance.yahoo.com — GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?
    7. finance.biggo.com — Moderna Stock Up 650% This Year as Personalized Cancer ...
    8. dashd.ai — Moderna Stock Soars 650% as Cancer Vaccine Sparks $88.5B ...
    9. www.marketbeat.com — Moderna (NASDAQ:MRNA) Shares Up 4% - Here's What Happened
    10. www.wireisrael.com — Moderna Leads S&P 500 With 652% Surge Despite Volatile Cancer ...
    11. finance.biggo.com — Moderna Soars 4-Fold in Three Months as Wall Street Warns of ...
    12. en.asiatoday.co.kr — Moderna shares surge on cancer vaccine results
    confidence 95%
  7. Moderna Shares Double on Cancer Vaccine Success

    Moderna shares surged after a late-stage clinical trial showed that a personalized mRNA cancer vaccine developed with Merck, when combined with Keytruda, significantly lowered the risk of melanoma recurrence or death. Six melanoma specialists evaluated the data as a clinically meaningful advancement for surgical patients, despite an initial sell-the-news reaction driven by valuation concerns. The custom-made treatment targets cancer cells left behind after surgery, though overall survival data remain immature and the commercial trajectory hinges on upcoming regulatory milestones and clinical developments.

    Why it matters

    The collaboration between Moderna and Merck represents a major test for applying messenger RNA technology beyond infectious diseases. While the Phase 3 trial results exceed previous analyst expectations, commercial success depends on navigating approval processes and proving long-term patient survival benefits.

    What is confirmed

    • A custom-made vaccine helps the immune system hunt down cancer cells left behind after surgery.

    What to watch next

    • Upcoming regulatory milestones
    • Maturation of overall survival data
    • Long-term commercial impact assessments
    Sources used for this update (7)
    1. www.cnn.com — Breaking News, Latest News and Videos | CNN
    2. www.merck.com — Merck | Home
    3. www.ajmc.com — Spring 2023 Conference Coverage | AJMC
    4. www.ynetnews.com — Great Britain
    5. www.medicaldaily.com — Salmonella Found in All Eight Oyster Samples From Virginia's Closed Little Wicomico River as Case Counts Diverge
    6. www.schwab.com — Q3 Health Care Earnings: Pharma Patent Cliffs | Charles Schwab
    7. www.zmescience.com — A Cancer Vaccine Custom-Made from Each Patient’s Own Tumor Reduced Melanoma Recurrence Risk by 42 Percent
    confidence 80%
  8. Melanoma Vaccine Results Trigger Sell-The-News Event

    An experimental personalized mRNA cancer vaccine developed by Moderna and Merck, combined with the immunotherapy Keytruda, reduced the risk of melanoma recurrence or death by 42 percent and disease spread by 38 percent in a late-stage trial. Six melanoma specialists evaluated the data as a clinically meaningful advancement for patients who underwent surgery. Despite outperforming analyst predictions, the positive Phase 3 trial data triggered a sell-the-news stock reaction due to the Cambridge-based company's high valuation. Overall survival data remain immature, and the long-term commercial impact depends on upcoming regulatory milestones.

    Why it matters

    The Phase 3 trial success follows an earlier massive rally driven by prior trial results and a fair value estimate adjustment to US$122.67 per share. Moderna previously returned Juan Andres as Chief Operating Officer to scale oncology manufacturing and re-entered the Nasdaq-100 index. Analysts noted that despite meeting expectations, the valuation pressure outweighed the positive medical data release.

    What is confirmed

    • The personalized mRNA cancer vaccine combined with Keytruda cut the risk of melanoma recurrence or death by 42 percent in a Phase 3 trial.
    • The combination treatment reduced disease spread by 38 percent.
    • Six melanoma specialists stated the results represent a clinically meaningful result for patients who underwent surgery.

    Still unconfirmed

    • The negative stock reaction was exclusively caused by Cambridge-based Moderna having a fat valuation despite beating analyst predictions.

    What to watch next

    • Release of mature overall survival data from the Phase 3 trial
    • Further regulatory updates regarding intismeran autogene
    Sources used for this update (7)
    1. seekingalpha.com — Patient Capital Management Q3 2026 Commentary
    2. www.yahoo.com — Merck/Moderna cancer vaccine cuts risk of death or recurrence ...
    3. www.cnbc.com — Moderna, Merck's cancer vaccine data a major advancement - CNBC
    4. wsvn.com — Experimental mRNA vaccine cuts risk that melanoma returns by 42% - WSVN 7News | Miami News, Weather, Sports | Fort Lauderdale
    5. www.bostonglobe.com — Moderna, Merck cancer vaccine met key endpoints in melanoma ...
    6. www.medicaldaily.com — Personalized mRNA Melanoma Vaccine Cut Recurrence or Death Risk 42% in Phase 3 Trial, but Survival Data Pending - Medical Daily
    7. www.ajmc.com — A Timeline of COVID-19 Vaccine Developments in 2021 | AJMC
    confidence 95%
  9. Moderna-Merck Cancer Vaccine Cuts Relapse Risk by 42 Percent

    Moderna and Merck released top-line results showing their personalized mRNA cancer vaccine, intismeran autogene, combined with the immunotherapy Keytruda reduced the risk of melanoma relapse or death by 42 percent in a late-stage trial. Despite meeting Wall Street expectations, the data release triggered a sell-the-news stock reaction, causing shares of both companies to fall following an earlier massive rally driven by prior trial success and a fair value estimate adjustment to US$122.67 per share. Moderna also returned Juan Andres as Chief Operating Officer to scale oncology manufacturing and re-entered the Nasdaq-100 index.

    Why it matters

    The Phase 3 melanoma trial success marks a major milestone for messenger RNA technology beyond infectious diseases. The therapy uses a personalized approach to train the immune system against specific tumor markers. Market watchers are closely tracking commercial scaling efforts as the company prepares for broader oncology deployment.

    What is confirmed

    • Moderna and Merck report their personalized mRNA cancer vaccine combined with Keytruda cut the risk of relapse or death by 42 percent in a melanoma study.
    • The latest top-line results follow previously reported trial successes for intismeran autogene.
    • The landmark melanoma study met Wall Street expectations but triggered a sell-the-news reaction that caused Moderna and Merck shares to fall.

    Still unconfirmed

    • Analysts suggest the stock pullback represents typical profit-taking and a sell-the-news market response following an eagerly anticipated data release.

    What to watch next

    • Long-term survival data updates from the late-stage melanoma trial
    • Regulatory filing timelines for the intismeran autogene and Keytruda combination
    Sources used for this update (5)
    1. www.forbes.com — Download The Forbes App
    2. arstechnica.com — Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
    3. www.scientificamerican.com — Here’s what Moderna’s latest mRNA cancer vaccine data actually show
    4. www.grandviewresearch.com — DNases, Ligases, And RNA Polymerases Market (2026 - 2033)
    5. www.biopharmadive.com — Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
    confidence 95%
  10. Moderna Shares Double on Cancer Vaccine

    Moderna shares have more than doubled following successful Phase 3 trial results for its personalized cancer vaccine candidate, intismeran autogene, which was developed alongside Merck. The late-stage melanoma trial demonstrated improvements in recurrence-free and distant metastasis-free survival. Despite a subsequent 10 percent pullback from profit-taking, the massive stock rally pushed values up over 600 percent this year, trading above Wall Street analyst price targets with a fair value estimate adjusted to US$122.67 per share. The company also returned former manufacturing leader Juan Andres to the role of Chief Operating Officer to manage oncology scaling and rejoined the Nasdaq-100 index.

    Why it matters

    The remarkable surge in Moderna shares stems from a major clinical milestone in the oncology sector, validating the commercial potential of mRNA technology beyond infectious diseases. To manage the upcoming operational demands, the company re-engaged veteran manufacturing executive Juan Andres. Financial markets responded by pushing the valuation past initial analyst projections.

    What is confirmed

    • Moderna shares surged over 600 percent this year following positive Phase 3 results for its personalized cancer vaccine candidate, intismeran autogene.
    • The late-stage melanoma trial for intismeran autogene improved recurrence-free and distant metastasis-free survival.
    • Moderna brought back former manufacturing leader Juan Andres as Chief Operating Officer to oversee oncology scaling.
    • Moderna was added back to the Nasdaq-100 index.

    What to watch next

    • Updates on oncology scaling and manufacturing execution under Chief Operating Officer Juan Andres
    • Further market adjustments to the US$122.67 per share fair value estimate by Wall Street analysts
    Sources used for this update (2)
    1. help.naver.com — Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide | ZeroHedge
    2. www.biopharmadive.com — Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study
    confidence 100%
  11. Moderna Shares Pull Back 10 Percent Following Cancer Vaccine Surge

    Moderna shares fell 10 percent as profit-taking hit the stock following a massive rally driven by positive Phase 3 results for its personalized cancer vaccine candidate, intismeran autogene, developed with Merck. The late-stage melanoma results, which improved recurrence-free and distant metastasis-free survival, helped drive the stock up over 600 percent this year. The company was also added back to the Nasdaq-100 index and brought back former manufacturing leader Juan Andres as Chief Operating Officer to oversee oncology scaling. Following the milestone, Moderna trades above Wall Street analyst price targets, and analysts have adjusted its fair value estimate to US$122.67 per share.

    Why it matters

    The recent stock movements mark a strategic shift for Moderna away from its heavy reliance on COVID-19 vaccines toward oncology and broader RNA-based therapeutics. The biotechnology firm is positioned to play a role in a national effort to combat cancer, supported by initiatives to accelerate vaccine development. However, analysts maintain varied stances on how to value the pipeline as the company prepares for upcoming data readouts.

    What is confirmed

    • Moderna shares fell 10 percent after a rally driven by its cancer vaccine progress.
    • The company reported positive Phase 3 results for its personalized cancer vaccine candidate, intismeran autogene, developed with Merck for melanoma patients.
    • Moderna was added back to the Nasdaq-100 index.
    • Juan Andres returned as Chief Operating Officer to oversee scaling for the personalized cancer vaccine.
    • Moderna's fair value estimate was updated by analysts from US$119.56 to US$122.67 per share.

    Still unconfirmed

    • Profit takers may possess information regarding an upcoming critical trial readout later this month that is unknown to market bulls.

    What to watch next

    • Critical trial readouts scheduled for later this month
    • Further analyst revisions regarding oncology revenue assumptions and price targets
    Sources used for this update (19)
    1. www.foxbusiness.com — Health Care
    2. github.com — nocache/README at master · Feh/nocache · GitHub
    3. finance.yahoo.com — Why Moderna Stock Surged Today
    4. finance.yahoo.com — Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?
    5. www.marketresearchfuture.com — RNA Based Therapeutics Market
    6. finance.yahoo.com — Moderna (MRNA) Is Up 18.4% After Cancer Vaccine Milestone And Nasdaq-100 Return Has The Bull Case Changed?
    7. finance.yahoo.com — Moderna (MRNA) Stock Sees Modest Fair Value Lift After Cancer Vaccine Analyst Revisions
    8. www.biospace.com — Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings
    9. finance.yahoo.com — Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?
    10. finance.yahoo.com — Moderna Stock Skyrockets on Reports of U.S. Cancer Vaccine ...
    11. contents.premium.naver.com — 📬 미국 주식 데일리 종목 분석 (2026.10.13)
    12. www.timothysykes.com — MRNA Stock Surges On Cancer Vaccine Catalysts And Nasdaq-100 Move
    confidence 90%
  12. Moderna shares more than double on mRNA cancer vaccine success

    Moderna's shares have surged over 100% due to the success of its mRNA cancer vaccine, developed with Merck, which improved recurrence-free and distant metastasis-free survival in melanoma patients. The stock has risen nearly 600% this year, with a 202% increase since August 18. Moderna will replace Warner Bros. Discovery in the Nasdaq-100 index on October 9.

    Why it matters

    The success of Moderna's mRNA cancer vaccine has significant implications for the treatment of melanoma and potentially other cancers. The company's mRNA technology has shown promise in improving patient outcomes and has garnered substantial investor attention. This growth comes as Moderna continues to expand its product pipeline and explore new applications for its mRNA technology.

    What is confirmed

    • Moderna's mRNA cancer vaccine combined with Keytruda succeeded in a late-stage trial for melanoma
    • Moderna shares rose 8% on October 5 as investors await full data on its melanoma vaccine trial
    • Moderna will replace Warner Bros. Discovery in the Nasdaq-100 index on October 9
    • Moderna's stock has surged nearly 600% this year
    • Moderna's stock has risen 202% since August 18

    Still unconfirmed

    • The NIH plans to back a cancer-vaccine push

    What to watch next

    • Full data on Moderna's melanoma vaccine trial
    • FDA approval for Moderna's mRNA cancer vaccine
    • Progress of Moderna's other mRNA vaccine candidates
    Sources used for this update (12)
    1. www.modernatx.com — Pioneering mRNA technology - Moderna
    2. www.modernatx.com — Company Culture - Moderna
    3. finance.yahoo.com — Moderna, Inc. (MRNA) Stock Price, News, Quote & History - Yahoo...
    4. www.cnn.com — Moderna and Merck say melanoma vaccine succeeded in large trial
    5. products.modernatx.com — Find vaccines by Moderna near you
    6. products.modernatx.com — mNEXSPIKE® (COVID-19 Vaccine, mRNA) by Moderna
    7. en.wikipedia.org — Moderna - Wikipedia
    8. www.biopharmadive.com — Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug | BioPharma Dive
    9. cepa.org — Forging a Transatlantic Biotechnology Partnership to Confront the China Challenge - CEPA
    10. finance.yahoo.com — MRNA Stock Sets New 52-Week High As Nasdaq-100 Reentry Meets NIH Cancer-Vaccine Push
    11. finance.yahoo.com — Moderna stock hits 4-year high on planned national cancer ...
    12. www.nature.com — Bioengineering strategies for improving the immunogenicity of mRNA vaccines | Signal Transduction and Tar....
    confidence 85%
  13. Moderna Shares Climb as Company Re-enters Nasdaq-100

    Moderna shares rose 8% on October 5 as investors await full data on its melanoma vaccine trial. The stock has surged nearly 600% this year, with a 202% increase since August 18. This growth follows the success of intismeran autogene, a personalized cancer vaccine developed with Merck that improved recurrence-free and distant metastasis-free survival in melanoma patients. Nasdaq announced on October 1 that Moderna will replace Warner Bros. Discovery in the Nasdaq-100 index before the market opens on October 9.

    Why it matters

    The vaccine uses mRNA technology to target cancer cells. Moderna is currently preparing regulatory filings and intends to present comprehensive data at an international medical meeting. Market volatility persists as some analysts, including those at Citigroup, have issued downgrades despite the price surge.

    What is confirmed

    • Moderna shares rose 8% on October 5.
    • Moderna will join the Nasdaq-100 on October 9, replacing Warner Bros. Discovery.
    • Moderna shares increased 202% between August 18 and October 4.
    • Moderna developed the intismeran cancer vaccine in partnership with Merck.

    Still unconfirmed

    • Citigroup downgraded Moderna shares.

    What to watch next

    • Moderna's official entry into the Nasdaq-100 on October 9.
    Sources used for this update (5)
    1. www.biopharmadive.com — Lilly, Foghorn part ways; Wave’s FDA-approved plans | BioPharma Dive
    2. www.marketbeat.com — Promising Biotech Stocks Worth Watching - October 4th
    3. 247wallst.com — Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
    4. finance.yahoo.com — MRNA Stock Soars Ahead Of Slated Return To Nasdaq-100; Retail ...
    5. www.gurufocus.com — Moderna (MRNA) Shares Surge on Cancer Vaccine Optimism ...
    confidence 90%
  14. Moderna shares surge on cancer vaccine success

    Moderna's shares have more than doubled this year, driven by the success of its personalized cancer vaccine, intismeran autogene. The vaccine, developed in partnership with Merck, has shown statistically significant improvements in recurrence-free survival and distant metastasis-free survival in patients with melanoma. Moderna is preparing to file for regulatory approval and plans to present data at an upcoming international medical meeting.

    Why it matters

    Moderna's push into cancer vaccines marks a significant shift in focus beyond COVID-19. The company's mRNA technology has shown promise in treating various types of cancer, and its partnership with Merck has yielded positive results. This development has significant implications for the future of cancer treatment and Moderna's position in the pharmaceutical industry.

    What is confirmed

    • Moderna's shares have increased by over 550% in 2026
    • The company's personalized cancer vaccine, intismeran autogene, has shown statistically significant improvements in recurrence-free survival and distant metastasis-free survival in patients with melanoma
    • Moderna and Merck plan to present data at an upcoming international medical meeting and engage with regulators on filing submissions for intismeran autogene in combination with KEYTRUDA
    • Moderna will replace Warner Bros. Discovery in the Nasdaq-100 before markets open on October 9

    Still unconfirmed

    • Analysts warn that personalized manufacturing costs, capacity, and reimbursement could limit commercial success

    What to watch next

    • Regulatory approval for intismeran autogene
    • Data presentation at an upcoming international medical meeting
    • Commercial success and market impact
    Sources used for this update (11)
    1. www.merck.com — Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoin....
    2. finance.yahoo.com — From $63 To $195: Moderna’s Two-Month Rerating Isn’t Done
    3. www.biopharmadive.com — Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data | BioPharma Dive
    4. finance.yahoo.com — Why Moderna (MRNA) Is Up 29.1% After Melanoma Vaccine Success ...
    5. stocktwits.com — MRNA Stock Eyes Best Year Ever: Analyst Calls China’s AI Drug Lead ‘Baseless’ As Moderna Awaits Can....
    6. simplywall.st — Moderna (MRNA) Gains Ground On Cancer Vaccine Narrative As ...
    7. www.fool.com — Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?
    8. www.zacks.com — Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now? - September 30, 2026 - Zacks.com
    9. finance.yahoo.com — Citi delivers major verdict after Moderna’s remarkable 703% run
    10. www.biopharmadive.com — PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval | BioPharma Dive
    11. stocktwits.com — SLS, IBRX Stocks Draw Retail Chatter As MRNA Lands A Nasdaq-100 Spot – ‘It Will Be SLS Next’
    confidence 85%
  15. Moderna Shares Rise Following Pipeline Presentation and Vaccine Progress

    Moderna stock increased by 7.1% during an afternoon session after the company presented its vaccine pipeline at the Morgan Stanley Global Healthcare Conference. The company is preparing to file for its personalized cancer vaccine, intismeran, as it shifts focus beyond COVID-19. This growth follows Phase 3 trials for the melanoma vaccine that showed a recurrence risk reduction of roughly half across 1,137 patients. While Moderna expands into rare diseases and therapeutics, competitor BioNTech is restructuring its cancer pipeline after a 1.35 billion euro loss in the first half of 2026.

    Why it matters

    The personalized mRNA cancer vaccine market is a primary competition point between Moderna and BioNTech. Success in melanoma trials positions Moderna to diversify its revenue streams away from pandemic-era products. The company is collaborating with Merck on the development of this personalized treatment.

    What is confirmed

    • Moderna shares rose 7.1% in an afternoon session following a presentation at the Morgan Stanley Global Healthcare Conference.
    • Moderna is developing a personalized cancer vaccine program called intismeran.
    • Phase 3 trials for the melanoma vaccine involved 1,137 patients and reduced recurrence risk by roughly half.
    • BioNTech reported a 1.35 billion euro loss in the first half of 2026.

    Still unconfirmed

    • Moderna shares surged 9% because Phase 3 melanoma data won a Presidential Symposium slot.

    What to watch next

    • Official regulatory filing date for the intismeran vaccine
    • Updated financial results for BioNTech regarding its pipeline restructuring
    • Clinical trial data for Moderna's rare-disease pipeline
    Sources used for this update (5)
    1. finance.yahoo.com — Why Are Moderna (MRNA) Shares Soaring Today
    2. finance.yahoo.com — Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
    3. finance.yahoo.com — Cancer Vaccines Market Anticipates Impressive Growth Trajectory at a CAGR of 36% During the Forecast Period (2026-2036) | DelveInsight
    4. finance.yahoo.com — Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID
    5. www.elle.com — What to Know About the New Cancer Vaccine
    confidence 90%
  16. Moderna Shares Surge Following mRNA Cancer Vaccine Success

    Moderna shares more than doubled after Phase 3 trials for its intismeran autogene melanoma vaccine showed a reduction in recurrence risk by roughly half. The trial involved 1,137 patients. Despite the rally, the stock saw a 5.13 percent decline on August 24 as investors took profits. Moderna is currently competing with BioNTech in the personalized mRNA cancer vaccine market, while BioNTech is restructuring its cancer pipeline following a 1.35 billion euro loss in the first half of 2026.

    Why it matters

    The competition between mRNA leaders highlights a shift from pandemic response to oncology. Success in melanoma vaccines could establish a blueprint for treating other solid tumors. Market volatility reflects the high-risk nature of biotech clinical milestones.

    What to watch next

    • Further Phase 3 data for other cancer indications
    • Regulatory filing dates for intismeran autogene
    • BioNTech financial results for the second half of 2026
    Sources used for this update (19)
    1. jen.jiji.com — Quarta Repubblica, Nicola Porro returns tonight in prime time on Rete4
    2. jen.jiji.com — AfD soars in Saxony-Anhalt, Vannacci: "Merz has an ulcer, let no one sleep"
    3. jen.jiji.com — Champions League, today's results: successes for Aston Villa and Aek, Porto-City on the field
    4. jen.jiji.com — Vuelta a España, today 17th stage: schedule, route and where to watch it
    5. jen.jiji.com — Denmark, total ban on mobile phones in schools: they won't even be used during break time
    6. jen.jiji.com — US Open, today Zverev-Khachanov: schedule, head-to-head and where to watch it on TV
    7. jen.jiji.com — Yemen, Houthi rebels advance on the Red Sea: Dhubab and Perim island fall
    8. jen.jiji.com — Murder-suicide in Pietralata family: today the funerals of Valentina, Luca, and Bianca
    9. jen.jiji.com — Publishing: BolognaFiere in Gambero Rosso capital, 5.7 million operation (2)
    10. jen.jiji.com — Princess Kate Middleton makes surprise visit to hospital where she was treated for cancer, thanks doctors and meets patients
    11. jen.jiji.com — Iran-Houthi, double threat to oil routes. Saudi Arabia wants US raids in Yemen, Trump says no
    12. jen.jiji.com — Bob Mackie, 'sultan of sequins' who dressed Cher, Diana Ross and Carol Burnett, dies at 87
    confidence 100%
  17. Wall Street Focuses on BioNTech and Moderna Cancer Vaccines

    Wall Street attention has intensified around BioNTech and Moderna as both companies compete in the personalized mRNA cancer vaccine market. Moderna previously saw its shares more than double following positive Phase 3 results for its intismeran autogene melanoma vaccine. The 1,137-patient trial showed the neoantigen therapy reduced melanoma recurrence risk by roughly half, despite a subsequent 5.13 percent share price decline on August 24 due to profit-taking. Meanwhile, competitor BioNTech has faced financial headwinds, reporting a 1.35 billion euro loss for the first half of 2026 while restructuring and shifting focus toward its own cancer pipeline.

    Why it matters

    The rivalry highlights a major commercial and scientific push into personalized mRNA therapies beyond infectious diseases. While Moderna leverages strong late-stage trial outcomes to capture market interest, BioNTech is actively reorganizing its leadership and pipeline to compete in the oncology sector.

    What is confirmed

    • Wall Street has recently attracted considerable attention toward both BioNTech and Moderna regarding their cancer vaccine stocks.

    What to watch next

    • Further financial performance reports from BioNTech and Moderna
    • Updates on regulatory submissions or commercialization timelines for intismeran autogene and competitor cancer pipelines
    Sources used for this update (4)
    1. www.fool.com — BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
    2. jen.jiji.com — US Open, today Alcaraz-Wu - Live
    3. jen.jiji.com — Earthquake today in Cosenza, magnitude 3.7 tremor: felt throughout the province
    4. www.usatoday.com — Personalized mRNA cancer vaccines offer new hope. We explain
    confidence 100%
  18. Moderna mRNA Cancer Vaccine Success Contrast with BioNTech Restructuring

    Moderna shares more than doubled following positive Phase 3 results for its personalized mRNA cancer vaccine, intismeran autogene. The trial involving 1,137 patients showed the neoantigen therapy reduced melanoma recurrence risk by roughly half. While profit-taking led to a 5.13% decline on August 24, the results position Moderna against competitor BioNTech. BioNTech is currently restructuring, naming a successor to Sahin and reporting a 1.35 billion euro loss for the first half of 2026 as it shifts its focus toward its own cancer pipeline.

    Why it matters

    The success of intismeran autogene marks the first positive Phase 3 result for a neoantigen therapy. This development occurs as mRNA technology expands from infectious diseases into oncology. The financial disparity between the two companies highlights different trajectories in the commercialization of cancer vaccines.

    What is confirmed

    • Moderna's intismeran autogene reduced melanoma recurrence risk by roughly half in a 1,137-patient Phase 3 trial.
    • Moderna shares more than doubled before declining 5.13% on August 24.
    • BioNTech reported a 1.35 billion euro loss for the first half of 2026.
    • BioNTech is restructuring and naming a successor to Sahin.

    What to watch next

    • Regulatory filing dates for intismeran autogene
    • BioNTech's progress on its own cancer pipeline
    • Further fluctuations in Moderna share price following the Phase 3 results
    Sources used for this update (15)
    1. jen.jiji.com — Samurai Jay, technical problems during the concert: "He's off-key even with autotune"
    2. jen.jiji.com — Niger, chaos in Niamey: TV broadcasts interrupted
    3. jen.jiji.com — US Open, it begins: from Paolini to Djokovic, today's matches and where to watch them for free
    4. jen.jiji.com — MotoGP, Aragon GP arrival order and World Championship standings
    5. jen.jiji.com — Italy-Spain, Schengen halt expires today. Ceuta still in crisis
    6. jen.jiji.com — US Open, Djokovic and physical problems: vomiting and inhaler on court - Video
    7. jen.jiji.com — Ranucci, the perpetrators of the attack remain in prison
    8. jen.jiji.com — Rome, Ndicka stops: injury during warm-up against Lecce
    9. jen.jiji.com — Mario Calabresi leaves Chora Media: towards candidacy for mayor of Milan
    10. jen.jiji.com — Fired at 57, a man decides to travel Europe... with 900 euros
    11. jen.jiji.com — Blue Green Economy Award 2026, the awards ceremony on September 16 in Naples
    12. finance.yahoo.com — Is BioNTech Stock a No-Brainer Buy on the Dip?
    confidence 100%
  19. Moderna Cancer Vaccine Success Prompts Industry Shifts

    Moderna's personalized mRNA cancer vaccine, intismeran autogene, has demonstrated the first positive Phase 3 results for a neoantigen therapy, reducing melanoma recurrence risk by roughly half in a 1,137-patient trial. While Moderna shares initially more than doubled before a 5.13% decline on August 24 due to profit-taking, the success creates a contrast with competitor BioNTech. BioNTech is currently restructuring, naming a successor to Sahin and reporting a 1.35 billion euro loss for the first half of 2026 while pivoting toward its own cancer pipeline.

    Why it matters

    Personalized mRNA vaccines target specific mutations in a patient's tumor to prevent cancer from returning. These results validate the clinical viability of neoantigen technology but highlight the financial volatility of the biotech sector.

    What is confirmed

    • Intismeran autogene reduced melanoma recurrence risk by roughly half in a Phase 3 trial of 1,137 patients.
    • Moderna shares fell 5.13% on August 24 after previously more than doubling.
    • BioNTech reported a 1.35 billion euro loss for the first half of 2026.

    What to watch next

    • Further research to move personalized vaccines from trials to general clinic use
    • BioNTech's updated 2026 guidance following its restructuring
    Sources used for this update (6)
    1. jen.jiji.com — Europa League, today the draw for Milan and Juventus: time, pots, and where to watch it
    2. www.ad-hoc-news.de — BioNTech's Balancing Act: A New CEO, a Costly Pivot, and a Pipeline That Must Prove Itself
    3. www.newscase.com — BioNTech’s Sympathy Surge Masks a Structural Squeeze
    4. www.nature.com — The Moderna cancer vaccine offers hope — now we must speed up personalized therapies
    5. jen.jiji.com — Ranucci, Milena Gabanelli: "Change in leadership? Long live Report"
    6. jen.jiji.com — Extreme heat doesn't let up in the South, fiery weekend ahead: today 6 red alerts, respite in the North
    confidence 90%
  20. Moderna Stock Volatility Follows Phase 3 Cancer Vaccine Success

    Moderna shares experienced a sharp decline of 5.13% on August 24 following a period where the stock more than doubled. This volatility follows the August 19 announcement that intismeran autogene, a personalized mRNA vaccine developed with Merck, reduced melanoma recurrence risk by roughly half in a Phase 3 trial of 1,137 patients. While the clinical results mark the first positive Phase 3 outcome for a personalized neoantigen mRNA cancer vaccine, investors have since engaged in profit-taking and valuation resets, with analysts keeping price targets below the recent peak.

    Why it matters

    The trial success demonstrates the potential of personalized mRNA technology to treat cancer by targeting specific neoantigens. This represents a significant milestone in oncology, though market reactions highlight a gap between clinical achievement and long-term valuation.

    What is confirmed

    • Moderna and Merck reported that intismeran autogene reduced melanoma recurrence risk by roughly half in a Phase 3 trial involving 1,137 patients.
    • Moderna shares more than doubled initially after the vaccine announcement before falling 5.13% on August 24.
    • The intismeran autogene trial is the first personalized neoantigen mRNA cancer vaccine to yield positive Phase 3 results.

    What to watch next

    • FDA regulatory filing dates for intismeran autogene
    • Updated analyst price targets following the August 24 valuation reset
    Sources used for this update (4)
    1. en.protothema.gr — What K.M. & Tsipras say about the elections, the phantom investor and the crème de la crème, bonuses at Astieras & shipowners selling tankers
    2. www.usatoday.com — Moderna's personalized cancer vaccine shows promise. Here's why
    3. jen.jiji.com — Attack on Ranucci, tomorrow the interrogation of those arrested. The defense: "They will reiterate that they did not know Lavitola"
    4. jen.jiji.com — Farewell Dolly Parton, almost 20 million streams on Spotify: the highest of her career
    confidence 100%
  21. Moderna and Merck mRNA Cancer Vaccine Cuts Melanoma Recurrence by Half

    Moderna and Merck announced on August 19 that their personalized mRNA vaccine, intismeran autogene, reduced the risk of melanoma recurrence by roughly half in a Phase 3 trial of 1,137 patients. While the news initially drove Moderna shares to more than double, the stock fell 5.13% on August 24 as investors engaged in profit-taking and valuation resets. Analysts have maintained price targets below the stock's temporary peak despite the clinical success. The therapy represents the first positive Phase 3 result for a personalized neoantigen mRNA cancer vaccine.

    Why it matters

    The companies spent a decade overcoming logistical hurdles and pandemic-era obstacles to develop the treatment. This success validates the use of mRNA for individualized oncology treatments beyond infectious diseases. It also creates a positive outlook for other firms in the cancer vaccine sector.

    What is confirmed

    • Moderna and Merck announced on August 19 that intismeran autogene reduced melanoma recurrence risk by roughly half in 1,137 patients.
    • Moderna stock decreased by 5.13% on August 24 following an initial surge.
    • The development of the vaccine took a decade to overcome logistical and pandemic-era challenges.

    What to watch next

    • Regulatory filing dates for intismeran autogene
    • Analyst revisions to Moderna price targets
    • Expansion of trials to other cancer types
    Sources used for this update (5)
    1. en.protothema.gr — Mitsotakis’s order to “round up the ripe ones living off public money,” the Thessaloniki Fair, Tsipras and Samaras, the Spetses tip-offs, and is George Papandreou’s son ...
    2. www.statnews.com — Inside Moderna and Merck’s cancer vaccine triumph
    3. consent.yahoo.com — Moderna and Merck Cancer Vaccine Success Is Good News for CancerVax
    4. www.tradingkey.com — Moderna Inc Stock (MRNA) Moved Down by 5.13% on Aug 24: A Full Analysis
    5. www.techtimes.com — Personalized mRNA Cancer Vaccine Clears Phase 3: Melanoma Recurrence Cut by Half
    confidence 90%
  22. Moderna and Merck Report Positive Phase III Results for Melanoma Vaccine

    Moderna shares more than doubled following the announcement of positive Phase III trial results for intismeran, an mRNA-based individualized neoantigen therapy developed with Merck. The trial involved more than 1,000 patients and demonstrated that the vaccine helped prevent the return and spread of melanoma. The news also triggered stock surges for several sequencing companies. This development marks the first-ever positive Phase III results for an mRNA cancer vaccine, potentially opening the door for a wider range of oncology treatments.

    Why it matters

    Melanoma is the deadliest form of skin cancer. The vaccine uses personalized mRNA technology to target specific neoantigens in a patient's tumor. This approach differs from traditional treatments by tailoring the therapy to the individual's cancer profile.

    What is confirmed

    • Moderna shares more than doubled following the success of an mRNA cancer vaccine.
    • The vaccine, known as intismeran, is designed to treat melanoma.
    • Moderna and Merck reported the first-ever positive Phase III results for an mRNA-based cancer vaccine.

    Still unconfirmed

    • The vaccine helped prevent the return and spread of melanoma in a trial of more than 1,000 patients.
    • Shares of several sequencing companies surged following the announcement.

    What to watch next

    • Regulatory approval filings for intismeran
    • Expansion of mRNA vaccine trials to other cancer types
    Sources used for this update (4)
    1. www.livemint.com — It now seems possible to vaccinate against cancer
    2. omaha.com — Moderna, Merck breakthrough could usher in cancer vaccines
    3. www.genengnews.com — StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too
    4. www.theglobeandmail.com — Why Tempus AI Skyrocketed This Week
    confidence 90%
  23. Moderna Shares Soar on mRNA Cancer Vaccine Success

    Moderna's shares surged after its personalized mRNA cancer vaccine, developed with Merck, showed promise in a late-stage Phase III trial for melanoma. The vaccine aims to treat the deadliest form of skin cancer and could lead to broader mRNA-based oncology treatments. Both companies are preparing for a potential market debut of the therapy.

    Why it matters

    The success of the mRNA cancer vaccine could revolutionize cancer treatment and expand the use of mRNA technology in oncology. Moderna's stock has more than doubled, causing an estimated $5 billion loss for short sellers. The vaccine's potential market debut could significantly impact the pharmaceutical and biotech industries.

    What is confirmed

    • Moderna's shares rose sharply after a personalized mRNA cancer vaccine developed with Merck showed promise in a late-stage Phase III trial targeting melanoma.
    • The experimental mRNA vaccine successfully cleared phase 3 clinical trials, the last step necessary before it can be approved by the FDA.
    • If ongoing studies in other cancers produce similar results, the technology could influence far more than cancer care itself.

    Still unconfirmed

    • The vaccine could change America in 7 surprising ways.

    What to watch next

    • FDA approval of the mRNA cancer vaccine
    • Market debut of the therapy
    • Results of ongoing studies in other cancers
    Sources used for this update (7)
    1. www.aol.com — Moderna's Comeback Is Finally Taking Shape -- and There May Be More Upside Ahead
    2. en.sedaily.com — SK hynix to Buy Back, Cancel 40 Trillion Won in Shares; KOSPI Retakes 6,800
    3. en.sedaily.com — Korea to Build 2 More Chip Fabs in Honam, Adding to 6-Plus Plan by 2040
    4. www.cheddar.com — Big Business This Week: Bond Market Turmoil and The Broader Economy
    5. www.nationalgeographic.com — Why Scientists Say This Personalized Cancer Vaccine Could Be a Game-Changer
    6. www.newsweek.com — Moderna’s Cancer Vaccine Could Change America in 7 Surprising Ways
    7. www.edaily.co.kr — Samyang Biopharm Hits Limit-Up as Moderna-MSD Cancer Vaccine Data Spark mRNA Rally [K-Bio Pulse]
    confidence 85%
  24. Moderna Shares Surge Following Positive mRNA Cancer Vaccine Trial Results

    Moderna shares rose sharply after a personalized mRNA cancer vaccine developed with Merck showed promise in a late-stage Phase III trial targeting melanoma. Market reactions varied by source, with reports of stock increases ranging from 90% to 177%, causing an estimated $5 billion loss for short sellers. The vaccine aims to treat the deadliest form of skin cancer and could lead to a broader wave of mRNA-based oncology treatments. Both companies are now preparing for a potential market debut of the therapy.

    Why it matters

    This development marks a shift for Moderna from COVID-19 vaccines toward personalized cancer treatment. The partnership with Merck (MSD) focuses on using mRNA technology to trigger specific immune responses against tumors. Success in melanoma trials serves as a proof of concept for applying similar technology to other cancer types.

    What is confirmed

    • Moderna and Merck developed an mRNA cancer vaccine that showed promise in a late-stage trial.
    • The vaccine is designed to treat melanoma.
    • Moderna stock experienced a significant price increase following the trial results.
    • The vaccine uses personalized mRNA technology.

    Still unconfirmed

    • Moderna shares doubled.

    What to watch next

    • Regulatory filing and approval dates for the melanoma vaccine
    • Expansion of Phase III trials to other cancer types
    • Official revenue projections for the vaccine market debut
    Sources used for this update (10)
    1. CNBC — Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
    2. WSJ — Moderna Shares Double on Success of mRNA Cancer Vaccine
    3. Bloomberg.com — Moderna’s 160% Surge Burns Shorts in ‘Painful’ $5 Billion Loss
    4. Clinical Trials Arena — MSD and Moderna eye cancer vaccine market debut on Phase III melanoma score
    5. KOMO — 'Another weapon' against cancer: Personalized mRNA vaccine shows promising results
    6. Reuters — Moderna, Merck breakthrough could usher in wave of cancer vaccines
    7. CBS News — Doctors explain how Moderna's melanoma mRNA vaccine could fight deadliest form of skin cancer
    8. Yahoo Finance — Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today?
    9. The New York Times — From Covid to Cancer: How Moderna’s Stock Jumped 177% in a Day
    10. STAT — One of the most consequential year for cancer treatment, ever
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community